• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Cardiology

Glucose control by closed-loop therapy in type 1 diabetes does not decrease C-peptide secretion

byAndrew LeeandKiera Liblik
September 9, 2022
in Cardiology, Endocrinology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. In type 1 diabetes patients, C-peptide levels were not significantly different between a closed-loop treatment group compared to controls at 12 months. 

2. Participants on closed-loop treatment had a higher percentage of time in the target glucose range than the control group.

Evidence Rating Level: 1 (Excellent)

Study Rundown: C-peptide secretion is a marker of residual functioning beta cells in type 1 diabetes. It is also predictive of glycemic control and microvascular complications. A hybrid closed loop therapy system automatically titrates insulin to blood sugar levels identified within the same device, which leads to better glycemic control. The present study compared C-peptide levels and glycemic indices in diabetes patients randomized to either closed-loop therapy or control groups. C-peptide levels at 12 months were not significantly different between the treatment and control groups. Measured C-peptide levels decreased in both trial groups during the study. The percentage of time within the target glucose range was higher in the closed-loop group than in the control group. Further, the time spent in a hyperglycemic state, glucose over 180 mg, was lower in the closed-loop group than in the control group. The total, basal, and bolus insulin doses were similar between both groups. Additionally, both groups had similar blood pressure, lipid profile, and body mass index (BMI). This multicenter, randomized control trial had a representative trial population and real-world environment for youth with type 1 diabetes, which strengthens the study results for generalizability. The study suggests that intensive glycemic control is important irrespective of the effect on C-peptide secretion.

Click to read the study in NEJM

Relevant Reading: A randomized trial of closed-loop control in children with type 1 diabetes

In-Depth [randomized control trial]: The Closed Loop from Onset in Type 1 Diabetes (CLOuD) trial is a multicenter, open-label, parallel-group, randomized trial comparing a closed-loop insulin delivery system and standard insulin therapy (n=97). Participants required a diagnosis of type 1 diabetes within the past 21 days and were between ages 10 to 16.9. Participants were followed for 24 months and had follow-up visits in 3-month intervals. The primary endpoint was the mean area under the receiver operating characteristic curve (AUC) for the plasma C-peptide level at 12 months after diagnosis. The AUC for C-peptide levels between both groups was not significantly different; the mean adjusted difference was -0.06 pmol per milliliter (95% Confidence interval [CI], -0.14 to 0.03). The percentage of time within the target glucose range at 12 months was higher in the closed-loop group (64±14%) than in the control group (54±23%; 95% CI, 2 to 7). At 24 months, no significant difference was seen between groups for the AUC for C-peptide (95% CI, -0.14 to 0.06). The percentage of time in the target glucose range at 12 months was higher in the closed-loop group than in the control group (95% CI, 6 to 21). The glycated hemoglobin was 11 mmol per mole in the closed-loop group and 15 mmol per mole in the control group at 24 months (95% CI, 7 to 15). The mean difference in the percentage of time with glucose levels lower than 70 mg per deciliter was 2.8% (95% CI, -0.6 to 6.2). A total of five cases of severe hypoglycemia were recorded, which involved 3 participants in the closed-loop group and 1 in the control group. In summary, residual C-peptide secretion may not be impacted by glycemic control.

RELATED REPORTS

Catheter ablation reduces rates of persistent atrial fibrillation and atrial tachyarrhythmia

Deep intronic FGF14 repeat expansion associated with late-onset cerebella ataxia

Chronic obstructive pulmonary disease associated with worse postoperative outcomes

Image: PD

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: C-peptidecardiologychronic diseaseClosed loop insulin therapyClosed loop therapyendocrinologyGlycated hemoglobinglycemic controltype 1 diabetes
Previous Post

Elevated plasma levels of SARS-CoV-2 antigen are associated with increased severity of illness

Next Post

Comparison between Roux-en-Y Gastric Bypass to sleeve gastrectomy

RelatedReports

β-blockers linked to improved survival in preserved ejection fraction heart failure
Cardiology

Catheter ablation reduces rates of persistent atrial fibrillation and atrial tachyarrhythmia

January 27, 2023
Brain lesions on MRI linked with subsequent increased stroke risk
Chronic Disease

Deep intronic FGF14 repeat expansion associated with late-onset cerebella ataxia

January 27, 2023
2 Minute Medicine Rewind May 20, 2019
Chronic Disease

Chronic obstructive pulmonary disease associated with worse postoperative outcomes

January 26, 2023
Fish oil and aspirin did not reduce arteriovenous fistula failure: The FAVOURED trail
Cardiology

Empagliflozin use is associated with slower progression of chronic kidney disease

January 26, 2023
Next Post
Resident involvement may not increase postoperative complications in neurosurgery

Comparison between Roux-en-Y Gastric Bypass to sleeve gastrectomy

Childhood maltreatment increases suicide risk

Factors associated with mortality among homeless elderly in California

FDA-approved weight loss medications associated with weight loss at one year

2 Minute Medicine Rewind September 12, 2022

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • #VisualAbstract: Torsemide does not provide additional decrease in mortality compared to furosemide among patients hospitalized for heart failure
  • Community-based adult vision screening program increases access to eye care
  • Aspirin thromboprophylaxis noninferior to low-molecular-weight heparin in patients with fractures
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options